DS
CRVS icon

David Shaw’s Corvus Pharmaceuticals CRVS Stock Holding History

David Shaw’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
+133,177
New +$1.85M ﹤0.01% 3215
2026
Q1 		– Sell
-64,915
Closed -$500K – 4625
2025
Q4 		$500K Buy
64,915
+39,340
+154% +$310K ﹤0.01% 3930
2025
Q3 		$188K Buy
+25,575
New +$131K ﹤0.01% 4296

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

David Shaw's CRVS Position: Q2 2026 in Review

David Shaw opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 133,177 shares worth $1.99M. The stake represents ﹤0.01% of the portfolio and ranks #3215 among its holdings. This is a return to the name: David Shaw previously reported a position in CRVS as recently as Q4 2025.

David Shaw first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • David Shaw held 133,177 shares of Corvus Pharmaceuticals worth $1.99M as of Q2 2026.
  • Corvus Pharmaceuticals was a new David Shaw position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3215 holding.
  • David Shaw first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.